Senate Panel OKs Antitrust Package Aimed At Drug Pricing

By J. Edward Moreno (July 29, 2021, 6:03 PM EDT) -- The U.S. Senate Judiciary Committee passed a slew of bills Thursday that would increase the Federal Trade Commission's ability to crack down on a variety of anti-competitive practices that lawmakers say have driven up drug prices for years, sending the legislation to the floor for a vote.

The committee unanimously passed four bills through a voice vote, each of which goes after a specific tactic that lawmakers said name brand pharmaceutical companies often use to weaken competition, resulting in higher drug prices for consumers, in some cases by making that behavior presumptively illegal.

One bill, The Stop Stalling Act, bars pharmaceutical...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!